Leonard C. Glass

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Gregory Gaich, Jenny Y. Chien, Haoda Fu et al. · Cell Metabolism · 2013 · 867 citations · Full text

Obesity, Metabolic Syndrome, Health Sciences +10

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

John B. Buse, Richard M. Bergenstal, Leonard C. Glass et al. · Annals of Internal Medicine · 2011 · 503 citations

Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone

Yoshinori Miyazaki, Archana Mahankali, Masafumi Matsuda et al. · Diabetes Care · 2001 · 404 citations · Full text

Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients

Mandeep Bajaj, Swangjit Suraamornkul, Paul K. Piper et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 356 citations

Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes

Mandeep Bajaj, Swangjit Suraamornkul, Thongchai Pratipanawatr et al. · Diabetes · 2003 · 291 citations · Full text